Combining Deoxyglucose with ABT-263/737 to Kill Cancer Cells
Author Information
Author(s): Yamaguchi Ryuji, Janssen Edith, Perkins Guy, Ellisman Mark, Kitada Shinichi, Reed John C.
Primary Institution: Sanford-Burnham Medical Research Institute
Hypothesis
Can deoxyglucose enhance the effectiveness of ABT-263/737 in inducing apoptosis in cancer cells?
Conclusion
The combination of deoxyglucose and ABT-263/737 effectively induces apoptosis in cancer cells, suggesting a promising alternative to traditional cancer therapies.
Supporting Evidence
- 2DG pre-treatment significantly increased the efficacy of ABT-737 in killing cancer cells.
- Combination therapy led to over 95% cell death in certain cancer cell lines.
- 2DG did not alter Mcl-1 protein levels but disrupted its association with Bak.
Takeaway
This study shows that a sugar called deoxyglucose can help a cancer drug work better to kill cancer cells.
Methodology
Cancer cells were treated with deoxyglucose followed by ABT-263/737, and apoptosis was measured through caspase activation and cell viability assays.
Potential Biases
Potential bias in selecting cell lines that are sensitive to the treatment.
Limitations
The study primarily focused on specific cancer cell lines and may not be generalizable to all cancer types.
Participant Demographics
Human cancer cell lines including prostate, cervical, and breast cancer.
Statistical Information
P-Value
0.000000
Confidence Interval
95% confidence interval of this difference: from -20.98 to -1.36
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website